Multimodal Assessment and Characterization of Sicca Syndrome

Emelie Kramer 1, Tabea Seeliger 2, Thomas Skripuletz 2, Vega Gödecke 3,4, Sonja Beider 1, Alexandra Jablonka 1, Torsten Witte 1 and Diana Ernst 1*

1 Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany, 2 Department of Neurology, Hannover Medical School, Hannover, Germany, 3 Centre for Rare Diseases, Hannover Medical School, Hannover, Germany, 4 Department of Nephrology, Hannover Medical School, Hannover, Germany

Background: Sicca syndrome represents a heterogeneous group of conditions, such as Sjögren syndrome, causing xerophthalmia and xerostomia. This study characterizes in depth patients with Sicca syndrome and evaluates salivary gland ultrasound (SGUS).

Methods: Principal component analysis and hierarchical clustering of clinical parameters, such as ESSPRI, ESSDAI and laboratory data, were performed on all referrals for assessment of Sicca symptoms between October 2018 and March 2021. SGUS and labial gland biopsies were compared across groups.

Results: A total of 583 patients were assessed. Objective dryness was confirmed in 73% of the patients. Cluster analysis identified 3 groups with post-hoc analysis confirming distinct phenotypes: Somatic Group (283/583; 49%) with more frequent symptoms but limited objective dryness; Dry Without Autoimmune Features (DAF neg, 206/584; 35%), and Dry With Autoimmune Features (DAF pos, 94/584; 16%). DAF pos patients had highest autoantibody titers (anti-SSA(Ro) 240 vs. 3.6 vs. 3.8; \( p < 0.001 \)), most extra-glandular manifestations (\( p < 0.001 \)), and highest median SGUS Score (DAF pos: 8 [IQR 4–10] vs. SG: 2 [1–4] vs. DAF neg: 4 [2–5]; \( p < 0.001 \)). No tangible correlation with primary Sjögren syndrome criteria was observed.

Discussion: SGUS score correlated with a subset of patients with Sjögren syndrome, identified in the DAF pos cluster. This study highlights heterogeneity within Sicca and, indeed, Sjögren syndrome, highlighting the need for further studies.

Keywords: sicca syndrome, Sjögren syndrome, lip biopsy, sicca symptoms, salivary gland ultrasonography (SGUS)

KEY NOTES

- Patients exhibiting sicca symptoms, including those fulfilling criteria for primary Sjögren syndrome, are inherently heterogeneous, with inconsistent findings on salivary ultrasound.
- Novel clustering of patients with sicca symptoms incorporating principal component analysis of numerous relevant factors revealed 3 distinct phenotypes with distinct patterns of salivary gland involvement on ultrasound.
- Correlation between these clustered phenotypes and traditional definitions was limited, but suggested that clinically distinct subgroups among patients with Sjögren syndrome exist.
- Refinement of distinct disease entities within primary Sjögren syndrome appears feasible, and salivary gland ultrasound may assist in discrimination. Implications for future studies and, ultimately, tailored therapies require further evaluation.
BACKGROUND

Sicca syndrome can be considered an overarching term for symptomatic ocular (xerophthalmia) and oral dryness (xerostomia). Dryness is common, particularly with increasing age, affecting up to 30% of the population over 65 years (1). Current diagnostic approaches focus on determining if an autoimmune etiology exists while excluding drug side effects or manifestations of other systemic diseases that can either induce hyposecretion or lacrimal gland destruction (2). Sjögren syndrome encapsulates the autoimmune sicca syndrome and may be considered as primary Sjögren syndrome (pSS) when occurring in apparent isolation or secondary in the presence of another recognizable autoimmune condition. In practical terms, diagnosis centers on clinical history, objective measurements of xerophthalmia and xerostomia, and auto-antibody profiling. pSS requires evidence of autoimmune inflammation of salivary or lacrimal glands, as outlined in the joint American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) classification criteria (3). These are deliberately broad, affording some heterogeneity in clinical features, but require either the presence of anti-SSA antibodies or evidence of lymphocytic sialadenitis on labial gland biopsy (LBx). Imaging is not required for the diagnosis of Sicca syndrome or the classification of pSS, but data for various modalities exist. Punctate calcification of parotid glands on computer tomography has demonstrated high diagnostic specificity, but utility is limited because of radiation exposure (4). Magnetic resonance imaging of the same glands has shown changes in both T1- and T2-weighted signal intensities (5). Salivary gland ultrasound (SGUS) has been purported as a low-cost and radiation-free alternative for many years, with hypoechoic lesions correlating with more severe disease in a variety of scoring systems (6–8). Furthermore, SGUS has proven to be an easily acquired diagnostic tool (9). Although specificity has been favorable, reported sensitivity has been moderate (10).

Given the inherent heterogeneity of such cohorts, such as the heterogeneous group of patients with pSS and varying manifestations, this finding is perhaps unsurprising (11, 12). The aim of this study is to independently assess the role of SGUS in a large, unselected Sicca syndrome cohort that has undergone extended-criteria phenotypic clustering.

METHODS

All patients referred for rheumatological assessment of suspected Sicca syndrome at our Institution between October 2018 and March 2021 were prospectively included. Structured clinical data, assessing symptoms, and ESSPRI and ESSDAI scores were collected. All the patients were tested for antinuclear and anti-SSA(Ro)/anti-SSB(La) antibodies, rheumatoid factor along with differential blood count, and standard biochemistry indices. Xerophthalmia was assessed by Schirmer test and xerostomia by Saxon test in all the patients, and < 3.5 g in 2 min (stimulated saliva flow) and < 5 mm in 5 min (lacrimal flow) were considered as reduced. LBx was performed in the patients with suspected pSS as indicated and graded according to Chisholm Mason Score, with grade ≥ 3 being considered diagnostic (13). SGUS consisted of bilateral assessment of both parotid and submandibular glands and was performed by 2 blinded sonographers experienced in the procedure. Image interpretation adhered to criteria defined by a score from 0 to 3 depending on homogeneity, and both cumulative totals and DeVita scores were considered in the analysis (6, 14). All scans were independently re-scored by the non-performing sonographer, and a consensus score derived from both scores was used in the analysis. In case of disagreement, the images were reviewed, and the lower scores were employed. All the participants provided informed written consent prior to inclusion, and the study was approved by the Institutional Review Board at Hannover Medical School (8179_BO_S_2018).

With the exception of SGUS and LBx scores, all collected continuous variables were included in a principal component analysis. Missing values were estimated by multiple imputation, and the calculated dimensions were evaluated by hierarchical clustering. The sensitivity and specificity of both SGUS and LBx within the identified clusters were then evaluated. All the statistical analyses were performed using R v4.0.3 (R Foundation, Vienna, Austria). Multiple imputations were performed using the missMDA package, and the FactoMineR package for principal component analysis and hierarchical clustering. Graphs were created using ggplot2, scatterplot3d, and rgl packages where appropriate. In cases where three or more groups were compared, Kruskal Wallis test was performed for categorical variables and ANOVA tests for comparing quantitative variables, where appropriate. The Mann-Whitney test was performed for two variables.
TABLE 1 | Comparing and contrasting the clinical demographics and attributes of the entire cohort subdivided into the three groups identified through principal component analysis and subsequent hierarchical clustering.

|                  | Somatic  | DAF<sub>neg</sub> | DAF<sub>pos</sub> | p-value |
|------------------|----------|-------------------|-------------------|---------|
| N (%)            | 283 (49) | 206 (35)          | 94 (16)           |         |
| Female, n (%)    | 239 (84) | 142 (69)          | 81 (86%)          | <0.001  |
| Age at Onset, years | 47.3 [36.6–55.9] | 60.2 [51.1–67.3] | 50.1 [35.5–59.4] | <0.001  |
| BMI, kgm<sup>-2</sup> | 26.1 [23.0–31.0] | 24.7 [21.7–27.7] | 24.6 [22.4–28.0] | 0.003   |
| Smoker, n (%)    | 50 (18)  | 15 (7)            | 4 (4)             | 0.06    |

ESSPRI Scores

|                  |          |               |               |         |
|------------------|----------|---------------|---------------|---------|
| Dryness          | 6 [3–7]  | 2 [1–3]       | 4 [2–4]       | <0.001  |
| Fatigue          | 8 [6–9]  | 3 [2–5]       | 5 [3–8]       |         |

Reported Symptoms

|                  |          |               |               |         |
|------------------|----------|---------------|---------------|---------|
| Raynaud, n (%)   | 86 (30)  | 51 (25)       | 44 (47)       | 0.006   |
| Arthralgia, n (%)| 222 (78) | 118 (57)      | 61 (65)       | 0.002   |
| Myalgia, n (%)   | 197 (70) | 87 (42)       | 40 (43)       | 0.003   |
| Stiffness, n (%) | 98 (35)  | 37 (18)       | 23 (25)       | 0.001   |
| Parotitis, n (%) | 62 (22)  | 24 (12)       | 33 (35)       | 0.001   |
| Sand corn*, n (%)| 168 (59) | 62 (30)       | 44 (47)       | 0.001   |
| Ocular Inflammation, n (%) | 120 (42) | 45 (22) | 26 (27) | 0.005 |

ESSDAI

|                  |          |               |               |         |
|------------------|----------|---------------|---------------|---------|
| -Score           | 5 [2–12] | 5 [0–11]      | 11 [4–17]     | <0.001  |
| Constitutional   |          |               |               | 0.02    |
| -None            | 194 (69) | 173 (84)      | 74 (79)       |         |
| -Low             | 79 (28)  | 26 (13)       | 16 (17)       |         |
| -Moderate        | 10 (3)   | 7 (3)         | 4 (4)         |         |
| Lymphadenopathy  |          |               |               | 0.09    |
| -None            | 232 (82) | 182 (88)      | 88 (94)       |         |
| -Low             | 50 (18)  | 24 (12)       | 4 (4)         |         |
| -Moderate        | 1 (<1)   | -             | 1 (1)         |         |
| -High            | -        | -             | 1 (1)         |         |
| Glandular Involvement, n (%) | 263 (93) | 197 (96) | 85 (90) | 0.21   |
| -None            | 19 (7)   | 8 (4)         | 8 (9)         |         |
| -Low             | 1 (<1)   | -             | 1 (1)         |         |
| Articular Involvement, n (%) | 241 (85) | 199 (97) | 73 (78) | 0.002   |
| -None            | 37 (13)  | 3 (1)         | 14 (15)       |         |
| -Low             | 4 (1)    | 4 (2)         | 7 (7)         |         |
| -Moderate        | 1 (<1)   | -             | -             |         |
| Cutaneous Involvement, n (%) | 262 (93) | 195 (95) | 83 (89) | 0.16   |
| -None            | 14 (5)   | 6 (3)         | 5 (5)         |         |
| -Low             | 7 (2)    | 4 (2)         | 6 (6)         |         |
| -Moderate        | 1 (<1)   | -             | -             |         |
| Pulmonary Involvement, n (%) | 251 (89) | 177 (86) | 73 (78) | 0.03   |
| -None            | 16 (6)   | 8 (4)         | 4 (4)         |         |
| -Low             | 12 (4)   | 11 (5)        | 11 (12)       |         |
| -Moderate        | 4 (1)    | 10 (5)        | 6 (6)         |         |
| Renal Involvement, n (%) | 279 (98) | 206 (100) | 89 (95) | 0.26   |
| -None            | 279 (98) | 206 (100)     | 89 (95)       |         |

(Continued)
TABLE 1 | Continued

| Somatic | DAF_{neg} | DAF_{pos} | p-value |
|---------|-----------|-----------|---------|
| -Low    | 2 (1)     | -         | -       | 3 (3)   |
| -Moderate | -     | -         | -       | 2 (2)   |
| -High   | 2 (1)     | -         | -       | -       |
| ESSDAI Muscular Involvement, n (%) | 0.38 |
| -None   | 272 (96)  | 197 (96)  | 87 (93) |
| -Low    | 5 (2)     | 6 (3)     | 1 (1)   |
| -Moderate | 4 (1) | 3 (1)     | 5 (5)   |
| -High   | 2 (-1)    | -         | -       | 1 (1)   |
| ESSDAI Peripheral Nerve Involvement, n (%) | 0.77 |
| -None   | 206 (73)  | 154 (75)  | 65 (69) |
| -Low    | 35 (12)   | 15 (7)    | 7 (7)   |
| -Moderate | 32 (11)  | 22 (11)   | 17 (18) |
| -High   | 10 (4)    | 15 (7)    | 5 (5)   |
| ESSDAI Central Nerve Involvement, n (%) | 0.13 |
| None    | 263 (93)  | 200 (97)  | 88 (94) |
| Moderate | 9 (3)    | 1 (-1)    | 2 (2)   |
| High    | 11 (4)    | 5 (2)     | 4 (4)   |
| ESSDAI Hematological Involvement, n (%) | 0.012 |
| -None   | 223 (79)  | 163 (79)  | 51 (54) |
| -Low    | 51 (18)   | 36 (18)   | 32 (34) |
| -Moderate | 8 (3)   | 6 (3)     | 11 (12) |
| -High   | 1 (-1)    | 1 (-1)    | -       |
| ESSDAI Biological Involvement, n (%) | <0.001 |
| -None   | 237 (84)  | 167 (81)  | 49 (52) |
| -Low    | 36 (13)   | 33 (16)   | 21 (22) |
| -Moderate | 10 (3)   | 6 (3)     | 24 (26) |
| Antibody Titres |          |       |         |
| -ANA ≥ 1:160 | 178 (63) | 152 (74) | 44 (47) | <0.001 |
| -RHF U/ml | 10.0 [10.0–10.9] | 10.0 [10.0–11.3] | 23.3 [11.7–71.0] | <0.001 |
| -Alpha-Fodrin U/ml | 9 [5–22] | 9 [6–19] | 12 [6–25] | 0.05 |
| -anti-SSA(Ro) U/ml | 3.6 [0.3–101.3] | 3.8 [0.3–102.3] | 240.0 [192.8–240.0] | <0.001 |
| -anti-SSB(La) U/ml | 0.4 [0.3–3.4] | 0.3 [0.3–1.9] | 73.1 [3.8–312.5] | <0.001 |
| Measurable Dryness |          |       |         |
| Saxon, g | 3.5 [2.4–4.9] | 4.2 [3.3–5.3] | 2.3 [0.6–3.7] | <0.001 |
| Schirmer, mm | 7.0 [2.0–17.9] | 3.0 [0.5–12.0] | 2.5 [0.0–7.1] | <0.001 |
| Labial Gland Biopsy, n (%) |          |       |         |
| -Biopsy performed | 150 (53) | 120 (58) | 18 (19) | |
| -Chisholm grade ≥3 | 66 (44) | 64 (53) | 9 (50) | |
| -Median Score | 2 [1–3] | 3 [2–3] | 3 [3–4] | |
| Salivary Gland Ultrasound, n (%) |          |       |         |
| -SGUS = 0 | 39 (14) | 39 (19) | 1 (1) | |
| -SGUS ≥ 6 | 73 (26) | 55 (27) | 38 (41) | |
| SGUS Score | 2 [1–4] | 4 [2–6] | 8 [4–10] | <0.001 |

The results are shown as mean and interquartile range unless stated otherwise. * Foreign body or grain of sand feeling in the eye.

RESULTS

A total of 583 patients were included; the majority of whom were female (462/583, 79%). Median age at symptom onset was 56 [interquartile range (IQR) 49.5–68] years. After subjective dryness, the most common symptoms were arthralgia (n = 401, 69%) and myalgia (n = 324, 56%). Objective dryness, defined as positive Schirmer and/or Saxon test, was observed in 425 (73%)
of the patients. None of those included had previously undergone radiotherapy or were receiving tricyclic antidepressants at the time of inclusion. Applying the ACR/EULAR pSS criteria across the cohort, in total, 231 (40%) fulfilled the classification criteria and 85 (15%) possessed none of required features (Supplementary Figure 1). A comprehensive summary of the entire cohort is included in the supplementary data. Following principal component analysis, hierarchical clustering identified three clearly demarcated groups (Figure 1), which were then phenotypically characterized in detail (Table 1).

Almost half (283/583; 49%) of the patients largely lacked objective abnormalities. Interestingly, these patients reported most subjective dryness, as well as highest pain and fatigue scores, and were referred to as the somatic group (SG). Just over a third of the patients (206/583; 35%) exhibited objective dryness mainly in the absence of autoimmune features (DAF_neg). Xerophthalmia was particularly prevalent, with patients being older and less likely to be female. Anti-SSA(Ro) antibodies were generally negative or of low titers in these patients. Ninety-four (16%) patients displayed objective dryness with autoimmune features (DAF_pos). These patients had the most severe xerophthalmia and xerostomia, most prevalent and markedly higher anti-SSA(Ro) antibody titers, and tended to be younger at the time of disease onset.

LBx was performed on only 288 (49%) of the patients. Given the high probability of selection bias, no statistical analysis was performed within the subgroups. A Chisholm grade ≥ 3 was observed in 139 (48%) of the biopsies performed. Of these, 101 (73%) were associated with a pathologic Saxon and/or Schirmer test, whereas only 34 (24%) corroborated a positive anti-SSA(Ro) antibody. The latter point may be at least partially explained by lower referrals for biopsy in anti-SSA(Ro)-positive patients. This can be seen within the clustered phenotypes, where only 19% of the DAF_pos patients underwent biopsy, compared to the 58% of DAF_neg and 53% of the SG. Although histologic grading tended to be slightly higher among the DAF_pos patients, the proportion of biopsies considered positive was similar across all the groups.

Salivary gland ultrasound (SGUS) was performed on all the patients, with cumulative scores ranging from 0 to 12 and a median score of 4 [IQR 2–6] across the entire cohort. Sixty patients (10%) had no detectable SGUS abnormality, and all but 2 were from the DAF_neg group (Supplementary Figure 2). Only 7 (7%) of the DAF_pos patients exhibited an SGUS total of < 5 (Supplementary Figure 2). Overall, the median SGUS score was lowest in the SGA 2 [IQR 1–4], with the DAF_neg group returning a median score of 4 [IQR 2–5]. Although the DAF_pos group scored much higher with a median of 8 [IQR 4–10], differences among all the groups proved highly significant (Figure 2). Furthermore, distinct patterns of glandular involvement were observed, with parotid involvement being almost exclusively occurring in the DAF_pos group (Supplementary Figure 3). With regard to fulfillment of pSS criteria in somatic and DAF_neg patients, a much higher proportion was observed in those with SGUS ≥ 6 vs. SGUS < 6 (84 vs. 55%). A full description of the relationship between pSS criteria and cumulative SGUS score is included in the supplementary data (Supplementary Figure 2).

**DISCUSSION**

This study evaluated the utility of SGUS in unselected patients referred for evaluation of Sjögren syndrome, and explored the relationship between Sicca syndrome and Sjögren syndrome beyond the ACR/EULAR criteria. Reported dryness proved an unreliable feature, with over a quarter of the patients lacking measurable xerophthalmia and xerostomia. Forty percent of the patients fulfilled the pSS criteria. Close scrutiny revealed significant heterogeneity among the patients, and indeed SGUS could not reliably characterize patients in this group. Given these observations and cohort size, we instead considered all available data to develop a more granular, inclusive characterization of sicca syndrome, better reflecting everyday clinical decision-making. This identified three distinct groups that were compatible with everyday clinical experiences. Clearly the DAF_pos group is small and represents a subgroup of more active pSS, given the higher ESSDAI scores and that all but one patient fulfilled the pSS criteria. However, sizable minorities in both the DAF_neg and SG groups also fulfilled the pSS criteria. Further interpretation comparing the calculated phenotypes and pSS should be discouraged, given the limited number of LBx performed. While ethically difficult to justify without a clear clinical indication, it is likely that fulfillment of the pSS criteria is underreported. Interestingly, positivity rates of labial gland biopsies were almost identical across all the groups.

The most significant finding was the exceptional correlation between the SGUS and DAF_pos patients, particularly with regard to parotid gland abnormalities. There has been some debate about the utility of SGUS as an additional criterion for pSS (15, 16), and our data would support its utility in identifying the most active patients. Indirectly, this corroborates a recent pSS study in which 29% of patients with pSS and low SGUS scores were considered to have milder disease (17).
Despite the large sample size, the retrospective nature of this analysis and the limited availability of LBx limit the interpretation of outcomes. Although both sonographers were blinded during data collection, further limitations arise from using only two observers. No adjustments were made for symptom duration before imaging. This would require serial rescanning and longitudinal analysis, which are beyond the scope of this study.

In conclusion, sicca syndrome comprises a heterogeneous group of conditions in which Sjögren syndrome remains an awkward fit. Performing novel statistical analysis on a broader range of parameters, three distinct phenotypes were identified. Parotid gland involvement in SGUS occurred almost exclusively in patients with autoimmune features. More research is needed to explore this relationship over time and further refine models evaluating sicca syndrome, and in turn assist treatment study design with a view to tailored therapy strategies.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board at Hannover Medical School (8179_BO_S_2018). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

EK: data collection, writing of the manuscript, database work, and patient flow. TSe: data collection and critical review. TSk, SB, AJ, and VG: critical review. TW: critical review and study design. DE: study design, organization, analyses, and writing of the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We would like to express our gratitude to the staff of the Rheumatology Outpatients Department at Hannover Medical School for their continual help in the organization of the patients: G Mielke, A Lahn, Dr. S Hirsch. This study was financially supported by Novartis and the Else Kröner-Fresenius Charity.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.777599/full#supplementary-material

REFERENCES

1. Baer AN, Walitt B. Update on sjogren syndrome and other causes of sicca in older adults. *Rheum Dis Clin North Am.* (2018) 44:419–36. doi: 10.1016/j.rdc.2018.03.002
2. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). *Ocul Surf.* (2007) 5:75–92. doi: 10.1016/S1542-0124(12)70081-2
3. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labeltoule M, Lietman TM, et al. 2016 American college of rheumatology/European league against rheumatism classification criteria for primary sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis.* (2017) 76:9–16. doi: 10.1136/annrheumdis-2016-210571
4. Sun Z, Zhang Z, Fu K, Zhao Y, Liu D, Ma X, et al. Diagnostic accuracy of parotid CT for identifying sjogren's syndrome. *Eur J Radiol.* (2012) 81:2702–9. doi: 10.1016/j.ejrad.2011.12.034
5. Takashima S, Takeuchi N, Morimoto S, Tomiyama N, Ikezoe I, Shogen K, et al. MR imaging of Sjogren syndrome: correlation with sialography and pathology. *J Comput Assist Tomogr.* (1991) 15:393–400. doi: 10.1097/00004728-199105000-00009
6. De Vita S, Lorenzon G, Rossi G, Sabella M, and Fossaluzza V. Salivary gland echography in primary and secondary Sjogren's syndrome. *Clin Exp Rheumatol.* (1992) 10:351–6.
7. Hocevar A, Ambrozic A, Rozman B, Kveder T, and Tomsic M. Ultrasonographic changes of major salivary glands in primary Sjogren's disease. *Clin Exp Rheumatol.* (2005) 44:678–72. doi: 10.1093/rheumatology/keh588
8. Theander E, Mandl T. Primary Sjogren's syndrome: diagnostic and prognostic value of salivary gland ultrasonography using a simplified scoring system. *Arthritis Care Res.* (2014) 66:1102–7. doi: 10.1002/acr.22264
9. Zabotti A, Zandonella Callegher S, Tullio A, Vukicevic A, Hocevar A, et al. Salivary gland ultrasonography in Sjogren's syndrome: a European multicenter reliability exercise for the harmonics project. *Front Med.* (2020) 7:581248. doi: 10.3389/fmed.2020.581248
10. Mossel E, Delli K, van Nimwegen JR, Stel A, Kroese FGM, Spikervet FKL, et al. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjogren's syndrome. *Ann Rheum Dis.* (2017) 76:1883–9. doi: 10.1136/annrheumdis-2017-211250
11. Sogkas G, Hirsch S, Olsson KM, Hinrichs JB, Thiele T, Seeliger T, et al. Lung Involvement in primary sjogren's syndrome—an under-diagnosed entity. *Front Med.* (2020) 7:332. doi: 10.3389/fmed.2020.00332
12. Seeliger T, Bonig L, Gingele S, Prenzler NK, Thiele T, Ernst D, et al. Nerve ultrasound findings in Sjogren's syndrome-associated neuropathy. *J Neuroimaging.* (2021) 31:1156–65. doi: 10.1111/jon.12907
13. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjogren's disease. *J Clin Pathol.* (1968) 21:656–60. doi: 10.1136/jcp.21.5.656
14. Milic VD, Petrovic RR, Boricic AV, Radunovic GL, Pejnovic NN, Soldatovic I, et al. Major salivary gland sonography in Sjogren's syndrome: diagnostic value of a novel ultrasonography score (0-12) for parenchymal inhomogeneity. *Scand J Rheumatol.* (2010) 39:160–6. doi: 10.3109/0300974090378623
15. van Nimwegen JR, Mossel E, Delli K, van Ginkel MS, Stel A, Kroese FGM, et al. Incorporation of salivary gland ultrasonography into the American college of rheumatology/European league against rheumatism criteria for primary sjogren's syndrome. *Arthritis Care Res.* (2020) 72:583–90. doi: 10.1002/acr.24017
16. Milic V, Covic J, Cirkovic A, Stanojovic S, Damjanov N, et al. Disease activity and damage in patients with primary Sjogren’s syndrome: prognostic value of salivary gland ultrasonography. *PLoS ONE.* (2019) 14:e0226498. doi: 10.1371/journal.pone.0226498
17. Zandonella Callegher S, Zabotti A, Giovannini I, Treppo E, Quartuccio L, De Vita S, et al. Normal-appearing salivary gland ultrasonography identifies a milder phenotype of primary sjögren's syndrome. *Front Med.* (2020) 7:602354. doi: 10.3389/fmed.2020.602354

**Conflict of Interest:** This study was financially supported by Novartis and the Else-Kröner Charity. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kramer, Seeliger, S Kripuletz, Gödecke, Beider, Jablonka, Witte and Ernst. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.